SI
CPRX icon

Sofinnova Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

Sofinnova Investments’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,549,552
Closed -$5.86M – 64
2018
Q3 		$5.86M Buy
1,549,552
+99,595
+7% +$312K 0.52% 34
2018
Q2 		$4.52M Buy
1,449,957
+1,301,902
+879% +$3.95M 0.51% 35
2018
Q1 		$354K Buy
+148,055
New +$492K 0.06% 39

Other funds holding CPRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sofinnova Investments's CPRX Position: Q4 2018 in Review

Sofinnova Investments sold out of Catalyst Pharmaceutical (CPRX) in Q4 2018, closing a stake of 1,549,552 shares — an estimated $5.86M sold.

Sofinnova Investments first reported a position in CPRX in Q1 2018 and held it in 3 quarters. The position peaked at $5.86M in Q3 2018. 86 funds tracked by Wall St. Rank hold CPRX as of Q4 2018.

  • Sofinnova Investments reported no remaining Catalyst Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • Sofinnova Investments sold 1,549,552 Catalyst Pharmaceutical shares in Q4 2018, an estimated $5.86M.
  • Sofinnova Investments first reported a position in Catalyst Pharmaceutical in Q1 2018 and held it in 3 quarters.
  • Sofinnova Investments's Catalyst Pharmaceutical position peaked at $5.86M in Q3 2018.
  • 86 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2018.

Based on Sofinnova Investments's 13F filing for Q4 2018, filed 14 Feb 2019.